# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-23-027820
Filing Date
2023-08-07
Accepted
2023-08-07 16:55:43
Documents
70
Period of Report
2023-06-30

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | bcrx-20230630.htm iXBRL | 10-Q | 1276640
2 | EX-10.1 | exhibit101-pharmakonloanag.htm | EX-10.1 | 1404090
3 | EX-10.3 | exhibit103-esppar20230707.htm | EX-10.3 | 73465
4 | EX-31.1 | bcrx-20230630xexx311.htm | EX-31.1 | 9585
5 | EX-31.2 | bcrx-20230630xexx312.htm | EX-31.2 | 9559
6 | EX-32.1 | bcrx-20230630xexx321.htm | EX-32.1 | 4626
7 | EX-32.2 | bcrx-20230630xexx322.htm | EX-32.2 | 4600
| Complete submission text file | 0001628280-23-027820.txt |  | 8618316

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
8 | XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT | bcrx-20230630.xsd | EX-101.SCH | 58979
9 | XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT | bcrx-20230630_cal.xml | EX-101.CAL | 52822
10 | XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT | bcrx-20230630_def.xml | EX-101.DEF | 232750
11 | XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT | bcrx-20230630_lab.xml | EX-101.LAB | 711707
12 | XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT | bcrx-20230630_pre.xml | EX-101.PRE | 422718
64 | EXTRACTED XBRL INSTANCE DOCUMENT | bcrx-20230630_htm.xml | XML | 896721

Mailing Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703
Business Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703 919-859-1302
BIOCRYST PHARMACEUTICALS INC (Filer) CIK: 0000882796 (see all company filings)

EIN.: 621413174 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-23186 | Film No.: 231148274
SIC: 2836 Biological Products, (No Diagnostic Substances)